Posted On: 11/02/2014 11:20:46 PM
Post# of 273322
Incyte Corp (INCY) 67.06 $INCY
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), LLY: 66.33 (-0.47), NVS: 92.69 (+0.74)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), ILMN: 192.58 (-0.84)
Upgrade Alert for Incyte (INCY)
Comtex SmarTrend(R) - Fri Oct 31, 6:57AM CDT
Incyte (NASDAQ:INCY) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $64.18 on volume of 2.5 million shares, above average daily volume of 1.1 million. Potential upside of 22.5% exists for Incyte, based on a current level of $64.18 and analysts' average consensus price target of $78.64. Incyte shares have support at the 200-day moving average (MA) of $53.86 and additional support at the 50-day MA of $50.86.
INCY: 67.06 (+2.88)
Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Business Wire - Thu Oct 30, 6:01AM CDT
--2014 guidance for Jakafi net product revenues increased to range of $350 million to $360 million, driven by continued strong growth in underlying demand
INCY: 67.06 (+2.88), NVS: 92.69 (+0.74)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.06 (+2.88), TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), ABBV: 63.46 (+2.28)
Buy These 5 Breakout Health Care Stocks for Healthy Gains
at The Street - Tue Oct 28, 9:30AM CDT
Health care stocks have the highest relative strength of any sector, an indication that they are outperforming the broad market through rallies and corrections alike.
PCYC: 130.67 (-3.93), CBST: 72.29 (-0.21), ABAX: 52.66 (+1.13), INCY: 67.06 (+2.88), HUM: 138.85 (+1.67)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 3.95 (-0.05), PTLA: 28.50 (+0.15), PCYC: 130.67 (-3.93), INCY: 67.06 (+2.88), AMGN: 162.18 (+0.60), SPPI: 7.58 (-0.07), BMY: 58.19 (-0.79), EGRX: 12.67 (-0.13), SGEN: 36.67 (+1.42), MRK: 57.94 (+0.63), CELGZ: 3.61 (+0.06)
Incyte to Present at the Nomura BioPharma Conference
Business Wire - Thu Oct 23, 7:00AM CDT
Incyte Corporation (Nasdaq:INCY) announced today it will present at the Nomura BioPharma Conference on Thursday, November 6, 2014 at 1:15 p.m. (EST) in Boston.
INCY: 67.06 (+2.88)
Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer
Business Wire - Fri Oct 17, 7:00AM CDT
Incyte Corporation (NASDAQ: INCY) today announced the appointment of David Gryska as Executive Vice President and Chief Financial Officer, effective October 31, 2014. Mr. Gryska will report to Herve Hoppenot, President and Chief Executive Officer.
INCY: 67.06 (+2.88)
Incyte to Report Third Quarter 2014 Financial Results on October 30
Business Wire - Wed Oct 15, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, October 30, 2014. The schedule for the press release and conference call is as follows:
INCY: 67.06 (+2.88)
Global Cancer Kinase Inhibitors Market & Pipeline Insight 2014: 649 Pipeline Drugs & 35 Marketed Drugs
M2 - Mon Oct 13, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btwzfw/global_cancer) has announced the addition of the "Global Cancer Kinase Inhibitors Market & Pipeline Insight" report to their offering. The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs. The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs. Additionally, with the industry undergoing the period of patent cliff, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients. Global Cancer Kinase Inhibitors Market & Pipeline Insight Report Highlights: - Classification & Mechanism of Kinase Inhibitors - Cancer Kinase Inhibitors Therapy Market Overview - Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country - Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country - Patent Analysis & Orphan Designation of Kinase Inhibitors - Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs - Marketed Cancer Kinase Inhibitors: 35 Drugs Key Topics Covered: 1. Introduction to Kinase Inhibitors 2. Kinase Inhibitors Classification 3. Mechanisms of Kinase Inhibitors 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 11. Competitive Landscape - AVEO Pharmaceuticals - Amgen - AstraZeneca - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Deciphera Pharmaceuticals - Genentech - GlaxoSmithKline - Incyte Corporation - Novartis - Pfizer - Takeda For more information visit http://www.researchandmarkets.com/research/bt...bal_cancer
INCY: 67.06 (+2.88), AVEO: 0.97 (-0.03), AMGN: 162.18 (+0.60), GSK: 45.49 (+0.35), NVS: 92.69 (+0.74)
Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 08, 7:14AM CDT
Sunesis's (SNSS) experimental cancer treatment failed to achieve the primary endpoint in a pivotal study, sending the shares down 78%.
VRTX: 112.64 (+1.79), CMRX: 31.04 (+1.15), GILD: 112.00 (-2.22), INCY: 67.06 (+2.88), ALXN: 191.36 (-1.57), SNSS: 1.70 (unch), REGN: 393.72 (+0.92)
Fallopian Tube Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b25z3h/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - MedImmune, LLC - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Astex Pharmaceuticals, Inc. - CTI BioPharma Corp. - Bayer AG - Incyte Corporation - Active Biotech AB - Oncolytics Biotech Inc. - OXiGENE, Inc. - Curis - Topotarget - NeoStem - Pharmacyclics - Synta - Oasmia - MabVax - Acceleron - Cerulean - OncoMed - TetraLogic Pharmaceuticals - Merrimack Pharmaceuticals, Inc. - Immunovaccine, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Clovis Oncology, Inc. - Recepta Biopharma S.A. - EGEN, Inc. - Sanofi Pasteur SA - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/b2...opian_tube
ONCY: 1.00 (+0.18), INCY: 67.06 (+2.88), IMGN: 9.26 (-0.23), AMGN: 162.18 (+0.60), LLY: 66.33 (-0.47), CTIC: 2.44 (+0.05), GSK: 45.49 (+0.35), OXGN: 2.36 (unch), MACK: 9.17 (-0.11), JNJ: 107.78 (+0.74), CLVS: 59.66 (+0.50), ABBV: 63.46 (+2.28), NVS: 92.69 (+0.74)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.72 (-0.01), IMMU: 3.95 (-0.05), ONCY: 1.00 (+0.18), OMED: 20.77 (-1.38), PFE: 29.95 (+0.11), INCY: 67.06 (+2.88), LLY: 66.33 (-0.47), GSK: 45.49 (+0.35), MNTA: 10.91 (-0.08), MACK: 9.17 (-0.11), SNTA: 2.96 (-0.05), INSY: 40.67 (-1.32), HALO: 9.62 (+0.01), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28), NVS: 92.69 (+0.74), CELGZ: 3.61 (+0.06)
Incyte Receives $60M Milestone Payment Related to Jakavi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:30AM CDT
Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe.
PSTI: 2.93 (-0.01), INCY: 67.06 (+2.88), NVS: 92.69 (+0.74), PDLI: 8.53 (+0.06)
Incyte announces USD60m milestone payment related to reimbursement of Jakavi (ruxolitinib) in Europe
M2 - Thu Oct 02, 7:28AM CDT
Biopharmaceutical company Incyte (NasdaqGS :INCY) said on Thursday that it will receive a USD60m milestone payment from Novartis related to reimbursement of Jakavi (ruxolitinib) in Europe from a prior collaboration and license agreement.
INCY: 67.06 (+2.88), NVS: 92.69 (+0.74)
Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi(R) (ruxolitinib) in Europe
Business Wire - Thu Oct 02, 6:30AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has earned a $60 million milestone payment from Novartis related to reimbursement of Jakavi(R) (ruxolitinib) in Europe. Incyte will record this amount as contract revenue in the third quarter, and expects to receive payment of $60 million in the fourth quarter.
INCY: 67.06 (+2.88), NVS: 92.69 (+0.74)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 27.70 (-0.35), PCYC: 130.67 (-3.93), RPTP: 9.61 (-1.40), INCY: 67.06 (+2.88), RGDO: 1.02 (-0.02)
Look for Shares of Incyte to Potentially Rebound after Yesterday's 1.74% Sell Off
Comtex SmarTrend(R) - Thu Sep 11, 5:18PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $49.38 to a high of $50.98. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $50.53 on volume of 940,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 67.06 (+2.88)
After Yesterday's Decline of 1.74%, Incyte Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 5:17PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $49.38 to a high of $50.98. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $50.53 on volume of 940,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 67.06 (+2.88)
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), LLY: 66.33 (-0.47), NVS: 92.69 (+0.74)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), ILMN: 192.58 (-0.84)
Upgrade Alert for Incyte (INCY)
Comtex SmarTrend(R) - Fri Oct 31, 6:57AM CDT
Incyte (NASDAQ:INCY) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $64.18 on volume of 2.5 million shares, above average daily volume of 1.1 million. Potential upside of 22.5% exists for Incyte, based on a current level of $64.18 and analysts' average consensus price target of $78.64. Incyte shares have support at the 200-day moving average (MA) of $53.86 and additional support at the 50-day MA of $50.86.
INCY: 67.06 (+2.88)
Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Business Wire - Thu Oct 30, 6:01AM CDT
--2014 guidance for Jakafi net product revenues increased to range of $350 million to $360 million, driven by continued strong growth in underlying demand
INCY: 67.06 (+2.88), NVS: 92.69 (+0.74)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.06 (+2.88), TEVA: 56.47 (unch), AMAG: 33.01 (-0.95), ABBV: 63.46 (+2.28)
Buy These 5 Breakout Health Care Stocks for Healthy Gains
at The Street - Tue Oct 28, 9:30AM CDT
Health care stocks have the highest relative strength of any sector, an indication that they are outperforming the broad market through rallies and corrections alike.
PCYC: 130.67 (-3.93), CBST: 72.29 (-0.21), ABAX: 52.66 (+1.13), INCY: 67.06 (+2.88), HUM: 138.85 (+1.67)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 3.95 (-0.05), PTLA: 28.50 (+0.15), PCYC: 130.67 (-3.93), INCY: 67.06 (+2.88), AMGN: 162.18 (+0.60), SPPI: 7.58 (-0.07), BMY: 58.19 (-0.79), EGRX: 12.67 (-0.13), SGEN: 36.67 (+1.42), MRK: 57.94 (+0.63), CELGZ: 3.61 (+0.06)
Incyte to Present at the Nomura BioPharma Conference
Business Wire - Thu Oct 23, 7:00AM CDT
Incyte Corporation (Nasdaq:INCY) announced today it will present at the Nomura BioPharma Conference on Thursday, November 6, 2014 at 1:15 p.m. (EST) in Boston.
INCY: 67.06 (+2.88)
Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer
Business Wire - Fri Oct 17, 7:00AM CDT
Incyte Corporation (NASDAQ: INCY) today announced the appointment of David Gryska as Executive Vice President and Chief Financial Officer, effective October 31, 2014. Mr. Gryska will report to Herve Hoppenot, President and Chief Executive Officer.
INCY: 67.06 (+2.88)
Incyte to Report Third Quarter 2014 Financial Results on October 30
Business Wire - Wed Oct 15, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, October 30, 2014. The schedule for the press release and conference call is as follows:
INCY: 67.06 (+2.88)
Global Cancer Kinase Inhibitors Market & Pipeline Insight 2014: 649 Pipeline Drugs & 35 Marketed Drugs
M2 - Mon Oct 13, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btwzfw/global_cancer) has announced the addition of the "Global Cancer Kinase Inhibitors Market & Pipeline Insight" report to their offering. The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs. The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs. Additionally, with the industry undergoing the period of patent cliff, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients. Global Cancer Kinase Inhibitors Market & Pipeline Insight Report Highlights: - Classification & Mechanism of Kinase Inhibitors - Cancer Kinase Inhibitors Therapy Market Overview - Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country - Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country - Patent Analysis & Orphan Designation of Kinase Inhibitors - Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs - Marketed Cancer Kinase Inhibitors: 35 Drugs Key Topics Covered: 1. Introduction to Kinase Inhibitors 2. Kinase Inhibitors Classification 3. Mechanisms of Kinase Inhibitors 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 11. Competitive Landscape - AVEO Pharmaceuticals - Amgen - AstraZeneca - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Deciphera Pharmaceuticals - Genentech - GlaxoSmithKline - Incyte Corporation - Novartis - Pfizer - Takeda For more information visit http://www.researchandmarkets.com/research/bt...bal_cancer
INCY: 67.06 (+2.88), AVEO: 0.97 (-0.03), AMGN: 162.18 (+0.60), GSK: 45.49 (+0.35), NVS: 92.69 (+0.74)
Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 08, 7:14AM CDT
Sunesis's (SNSS) experimental cancer treatment failed to achieve the primary endpoint in a pivotal study, sending the shares down 78%.
VRTX: 112.64 (+1.79), CMRX: 31.04 (+1.15), GILD: 112.00 (-2.22), INCY: 67.06 (+2.88), ALXN: 191.36 (-1.57), SNSS: 1.70 (unch), REGN: 393.72 (+0.92)
Fallopian Tube Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b25z3h/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - MedImmune, LLC - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Astex Pharmaceuticals, Inc. - CTI BioPharma Corp. - Bayer AG - Incyte Corporation - Active Biotech AB - Oncolytics Biotech Inc. - OXiGENE, Inc. - Curis - Topotarget - NeoStem - Pharmacyclics - Synta - Oasmia - MabVax - Acceleron - Cerulean - OncoMed - TetraLogic Pharmaceuticals - Merrimack Pharmaceuticals, Inc. - Immunovaccine, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Clovis Oncology, Inc. - Recepta Biopharma S.A. - EGEN, Inc. - Sanofi Pasteur SA - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/b2...opian_tube
ONCY: 1.00 (+0.18), INCY: 67.06 (+2.88), IMGN: 9.26 (-0.23), AMGN: 162.18 (+0.60), LLY: 66.33 (-0.47), CTIC: 2.44 (+0.05), GSK: 45.49 (+0.35), OXGN: 2.36 (unch), MACK: 9.17 (-0.11), JNJ: 107.78 (+0.74), CLVS: 59.66 (+0.50), ABBV: 63.46 (+2.28), NVS: 92.69 (+0.74)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.72 (-0.01), IMMU: 3.95 (-0.05), ONCY: 1.00 (+0.18), OMED: 20.77 (-1.38), PFE: 29.95 (+0.11), INCY: 67.06 (+2.88), LLY: 66.33 (-0.47), GSK: 45.49 (+0.35), MNTA: 10.91 (-0.08), MACK: 9.17 (-0.11), SNTA: 2.96 (-0.05), INSY: 40.67 (-1.32), HALO: 9.62 (+0.01), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28), NVS: 92.69 (+0.74), CELGZ: 3.61 (+0.06)
Incyte Receives $60M Milestone Payment Related to Jakavi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:30AM CDT
Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe.
PSTI: 2.93 (-0.01), INCY: 67.06 (+2.88), NVS: 92.69 (+0.74), PDLI: 8.53 (+0.06)
Incyte announces USD60m milestone payment related to reimbursement of Jakavi (ruxolitinib) in Europe
M2 - Thu Oct 02, 7:28AM CDT
Biopharmaceutical company Incyte (NasdaqGS :INCY) said on Thursday that it will receive a USD60m milestone payment from Novartis related to reimbursement of Jakavi (ruxolitinib) in Europe from a prior collaboration and license agreement.
INCY: 67.06 (+2.88), NVS: 92.69 (+0.74)
Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi(R) (ruxolitinib) in Europe
Business Wire - Thu Oct 02, 6:30AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has earned a $60 million milestone payment from Novartis related to reimbursement of Jakavi(R) (ruxolitinib) in Europe. Incyte will record this amount as contract revenue in the third quarter, and expects to receive payment of $60 million in the fourth quarter.
INCY: 67.06 (+2.88), NVS: 92.69 (+0.74)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 27.70 (-0.35), PCYC: 130.67 (-3.93), RPTP: 9.61 (-1.40), INCY: 67.06 (+2.88), RGDO: 1.02 (-0.02)
Look for Shares of Incyte to Potentially Rebound after Yesterday's 1.74% Sell Off
Comtex SmarTrend(R) - Thu Sep 11, 5:18PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $49.38 to a high of $50.98. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $50.53 on volume of 940,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 67.06 (+2.88)
After Yesterday's Decline of 1.74%, Incyte Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 5:17PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $49.38 to a high of $50.98. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $50.53 on volume of 940,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 67.06 (+2.88)
(0)
(0)
